CT for Evaluation & Treatment of Cardiovascular Disease

Slides:



Advertisements
Similar presentations
Lipid Management in 2015: Risk & Controversies
Advertisements

Rate of Obstructive Coronary Disease in Elective Diagnostic Cath Manesh R. Patel, MD Assistant Professor of Medicine Director Cath Lab Research – Duke.
Morteza Naghavi, M.D. Society for Heart Attack Prevention and Eradication (SHAPE) Detection and Treatment of Asymptomatic Atherosclerosis for Primary Prevention.
Electron Beam Computed Tomography in the Age of 64 Slice CT Matthew J. Budoff, MD, FACC Associate Professor of Medicine Division of Cardiology Harbor-UCLA.
The Efficacy of Non-invasive Diagnostic for CAD in PMK Hospital Maj. Hutsaya Prasitdumrong, M.D. Cardiovascular Division, Department of Internal Medicine,
Clinical Trials. Date & location – January-November 1998, stress SPECT patients randomly received tetrofosmin or sestamibi (n~1550) Inclusion criteria.
British Cardiac Intervention Society Risk Assessment In Acute Coronary Syndromes Dr David Newby BHF Senior Lecturer in Cardiology Associate Director of.
Coronary Artery Calcification & Computed Tomography Scoring.
Long-term predictive value of assessment of coronary atherosclerosis by contrast- enhanced coronary computed tomography angiography: meta- analysis and.
Morteza Naghavi, M.D. Founder Society for Heart Attack Prevention and Eradication (SHAPE) SHAPE Guidelines Prevention of Fatal Cardiovascular Events (Heart.
Overly concerning and falsely reassuring?? FRAMINGHAM RISK FACTORS IN THE ED.
Coronary Calcium Scoring for Risk Stratification and Guidelines Matthew Budoff, MD, FACC, FAHA Professor of Medicine Director, Cardiac CT Harbor-UCLA Medical.
Surrogate Measures of Atherosclerosis and Implications for Evaluating Cardiovascular Risk Nathan D. Wong, Ph.D., F.A.C.C. Associate Professor and Director.
Screening and Treatment of Coronary Artery Disease Matthew J. Budoff, MD, FACC Associate Professor of Medicine Division of Cardiology, Harbor-UCLA Medical.
Only You Can Prevent CVD Matthew Johnson, MD. What can we do to prevent CVD?
Tenth International Symposium HEART FAILURE & Co. CARDIOLOGY SCIENCE UPDATE FEMALE DOCTORS SPEAKING ON FEMALE DISEASES Milano aprile 2010 FEDERICA.
Screening for CAD: What Test to Order for Which Situation
Screening for Coronary Artery Calcium with Computed Tomography: Angiography and Intervention in Patients with Scores Over 400 Screening for Coronary Artery.
Exercise Echocardiography Cardiac Issues 2011 Douglass A Morrison, MD, PhD.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Mortality Incidence of Patients With Non-Obstructive Coronary Artery Disease Diagnosed by Computed Tomography Angiography Naser Ahmadi, MD, Vahid Nabavi,
HILLSBOROUGH COUNTY SHERIFF’S DEPARTMENT Saving Our Law Officers From Sudden Death and Heart Attacks.
Clinical Trial Results. org Long-Term Prognosis Associated with Coronary Calcification Matthew J. Budoff, MD, Leslee J. Shaw, PhD, Sandy T. Liu, Steven.
RITA-3 Is this a benign lesion in a benign condition? Who Needs Angioplasty in 2008? Stable Angina Stable Angina Keith A A Fox Professor of Cardiology.
Silent Ischemia STABLE CAD
Ethnic Differences in the Prognostic Value of Coronary Artery Calcification for All-Cause Mortality Khurram Nasir MD MPH, Leslee J. Shaw PhD, Sandy T.
Predictive Value of Coronary Calcium Scoring Matthew Budoff, MD, FACC, FAHA Associate Professor of Medicine UCLA School of Medicine Director, Cardiac CT.
Coronary Artery Calcium
Morteza Naghavi, M.D. Society for Heart Attack Prevention and Eradication (SHAPE) Houston, TX Screening for Early Detection and Prevention of Heart Attack.
The Century Health Trial A Comprehensive Integrated Strategy For Managing CAD K. Lance Gould, M.D. Martin Bucksbaum Distinguished University Chair, Professor.
Insights from the PROMISE Trial Neha J. Pagidipati, MD MPH; Kshipra Hemal; Adrian Coles, PhD; Daniel B. Mark, MD MPH; Rowena J. Dolor, MD MHS; Patricia.
Date of download: 5/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for.
CARDIAC CT IN SCREENING FOR CAD Hossein Nademi MD CARDIOLOGIST JAVADOL-A-EME HEART HOSPITAL OCT
Coronary Artery Disease Po Hu IMG 310 Sectional Anatomy for Medical Imaging Summer Pathology Presentation Project.
Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: Prognostic Value of Cardiac Computed Tomography.
Date of download: 6/23/2016 Copyright © The American College of Cardiology. All rights reserved. From: ACCF/SCAI/AATS/AHA/ASE/ASNC/HFSA/HRS/SCCM/SCCT/SCMR/STS.
Date of download: 6/25/2016 Copyright © The American College of Cardiology. All rights reserved. From: ACCF/SCCT/ACR/AHA/ASE/ASNC/NASCI/SCAI/SCMR 2010.
Matthew P. Ostrom, MD, Ambarish Gopal, MD, Naser Ahmadi, MD, Khurram Nasir, MD, MPH, Eric Yang, MD, Ioannis Kakadiaris, PHD, Ferdinand Flores, BS, Song.
Ischaemic heart disease. Coronary artery disease(CAD) is the leading cause of death worldwide. The rates of mortality and disability due to CAD are increasing.
Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: ACCF/ASNC/ACR/AHA/ASE/SCCT/SCMR/SNM 2009 Appropriate.
A Clinical and Echocardiographic Score for Assigning Risk of Major Events After Dobutamine Echocardiograms JACC Vol. 43, No June 2, 2004:2102–7.
Choosing Wisely: Cardiology Jeffrey Ziffra D.O. Mercy Medical Center – North Iowa 10/14/2016.
Coronary Artery Disease **CAD Risk Stratification**
Atherosclerotic Cardiovascular Heart Disease in Women
Women and Cardiovascular Disease
The Role of Cardiac CT in CHD Risk Assessment
Cardiac Indices in Myocardial Perfusion Scan and Their Impact on the Patient's Prognosis
18th Annual Primary Care and Cardiovascular Symposium
Risk Stratification of Chest Pain: Best Practices
Copyright © 2009 American Medical Association. All rights reserved.
Multi Modality Approach to Diagnosis of Ischemia in Post CABG Cases
Wm. Guy Weigold, MD, FACC, FSCCT Director of Cardiac CT
Clinical need for determination of vulnerable plaques
The Role of Cardiac CT in Women
Debate: What Does the Future Hold for the Treatment of Unprotected Left Main Disease? More PCI No More Routine Surgery Ron Waksman, MD, FACC Washington.
Journal of Nuclear Cardiology | Official Journal of the American Society of Nuclear Cardiology Prediction of 14-year cardiovascular outcomes by dobutamine.
Phenotype vs. Genotype: Defining Severe Familial Hypercholesterolemia
Use of Current CAC Guidelines and CAD Risk Evaluation in Asymptomatic Adult Women Gina Lundberg MD, Quira Woodbury MSc, Stacy Jaskwhich NP, Kevin Viel.
European Heart Association Journal 2007 April
Insights from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)
Section 9: Continuum of care: Summary and timeline
Role of CT Coronary Angiogram in pre-renal transplant evaluation
O.L.Reuchlin gebruik van CT binnen de cardiogie
Contemporary Evidence-Based Guidelines
What oral antiplatelet therapy would you choose?
CT coronary angiography and coronary calcium scoring
HILLSBOROUGH COUNTY SHERIFF’S DEPARTMENT
Preventative Cardiology
The following slides highlight a report on a presentation at the American College of Cardiology 2004, Scientific Sessions, in New Orleans, Louisiana on.
Requested Information by CMS Team During April 30th Hearing
Presentation transcript:

CT for Evaluation & Treatment of Cardiovascular Disease Wm. Guy Weigold, MD, FACC, FSCCT Director, Cardiac CT Washington Hospital Center Washington, DC

I have no real or apparent conflicts of interest to report. Wm. Guy Weigold, MD I have no real or apparent conflicts of interest to report.

Cardiac CT = Coronary CT Angiography

Cardiac CT also = Coronary Calcium Scan Preceded coronary CTA by 10 years (1990) Calcium scoring method Agatston, Janowitz, Hildner, Zusmer, Viamonte, Detrano Agatston AS et al. JACC 1990; 15:827-32

Calcification is an Integral Part of Arterial Wall Plaque Colocalizes with macrophages and SMC. Good correlation with overall plaque burden Poor correlation with stenosis in individual cases – though as CS rises, likelihood of stenosis increases

Incremental predictive value of CACS Arch Intern Med. 2004;164(12):1285-92

From JACC 2007 consensus: CHD death or MI Higher CAC scores associated with higher event (CHD death or MI) rates and higher RR ratios High risk rate: 4.6% Very high risk rate: 7.1% (rates at 3-5 years) Summary RR ratios reveal that higher CAC scores are associated with higher event rates and higher RR ratios. An average CAC risk score (CACS 1-112) associated with summary RR ratio of 1.9 compared to CACS=0. At higher risk scores, RR increases in an incremental fashion, to as high as 10.8 when CACS > 1000. Pools CHD death or MI rates at the “high risk” and “very high risk” categories were 4.6% and 7.1% at 3 to 5 yr. Greenland P, Bonow RO, Brundage BH, et al. JACC 2007;49:378-402.

Following this meta-analysis, 4 more prospective studies South Bay Heart Watch: Middle aged, higher risk PACC Project: Aged 40-50, low risk Taylor et al, JACC 2005;46:807-814 Greenland. JAMA 2004;291:210-215. Rotterdam: Elderly St. Francis: Middle aged 2-10X  risk Guerci et al. JACC 2005;46:158 Vliegenthart. Circulation 2005;112:572

Pooled data from 4 studies: Intermediate Framingham risk patients only (10-20% 10-yr risk) All patients initially classified as intermediate risk (10-20% 10-yr risk) based on Framingham Analysis of pooled data from 4 studies 19 20 22 28 looking only at individuals at intermediate risk by Framingham risk score demonstrates that while indeed the average risk was in the 10-20% 10-yr risk range, those in the highest tertile of CACS (400 or greater) actually had an event rate that meets the definition of HIGH 10-yr risk (>20% 10-yr risk). This suggesting that especially within this INTERMEDIATE risk group, there is heterogeneity, and that CACS can be used to identify individuals who, despite being at INTERMEDIATE Framingham risk, will actually face a HIGH-risk event rate. These patients would then be treated more aggressively, essentially with secondary prevention measures: lifestyle modification with weight loss, diet, and exercise; smoking cessation; a BP goal of 115/70; an LDL goal of 70; an HDL goal of ???; an A1c goal of ???; a ??? goal of ???.

Prognosis is excellent in setting of zero or very low CAC scores …but not 0 when CACS=0 Number of vessels involved is important Even with CAC < 100 Check journals: JACC, JACC imaging, Circ, Circ imaging, NEJM, JAMA, AJC, Arch IM, Annals IM for calcium J Am Coll Cardiol 2007;49:1860–70 11

The mortality rate associated with a CACS=0 is 0 The mortality rate associated with a CACS=0 is 0.87/1000 person-yr 44,052 asympto adults referred by risk ff; screening EBCT Men Women Blaha M, Budoff MJ, Shaw LJ, et al. JACC Img 2009;2:692-700

Meta-analysis of 71,595 asymptomatic adults Mean f/u 4 yr 29,312 (41%) had CACS=0  0.47% had event 42,283 had CAC  4.14% had event RR ratio 0.15 [0.11-0.21, p<0.001] Sarwar A, Shaw LJ, Shapiro MD, et al. JACC Img. 2009;2:675-88

Case Example 55 yr old man Total cholesterol: 170 mg/dL HDL cholesterol: 30 mg/dL Non-smoker Systolic BP: 133 mmHg (on medication) 10-yr Framingham risk: 10%

Case Example 55 yr old man 10-yr Framingham risk: 10% Agatston score: <100: No significant impact on CHD risk 100-400: 2-4x increase of CHD risk: high risk >400: 5-10x increased of CHD risk: high risk

2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults Developed in Collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance

Recommendations for Calcium Scoring Methods Measurement of CAC is reasonable for cardiovascular risk assessment in asymptomatic adults at intermediate risk (10% to 20% 10-year risk. Measurement of CAC may be reasonable for cardiovascular risk assessment in adults at low to intermediate risk (6% to 10% 10-year risk). Persons at low risk (<6% 10-year risk) should not undergo CAC measurement for cardiovascular risk assessment. B I IIa IIb III B I IIa IIb III B I IIa IIb III

Risk Assessment Considerations for Patients with Diabetes Mellitus In asymptomatic adults with diabetes, 40 years of age and older, measurement of CAC is reasonable for cardiovascular risk assessment. Measurement of hemoglobin A1C may be considered for cardiovascular risk assessment in asymptomatic adults with diabetes. Stress MPI may be considered for advanced cardiovascular risk assessment in asymptomatic adults with diabetes or when previous risk assessment testing suggests high risk of CHD, such as a CAC score of 400 or greater. B I IIa IIb III B I IIa IIb III I IIa IIb III

Recommendations for Myocardial Perfusion Imaging Stress MPI may be considered for advanced cardiovascular risk assessment in asymptomatic adults with diabetes or asymptomatic adults with a strong family history of CHD or when previous risk assessment testing suggests high risk of CHD, such as a coronary artery calcium (CAC) score of 400 or greater. Stress MPI is not indicated for cardiovascular risk assessment in low- or intermediate-risk asymptomatic adults. (Exercise or pharmacologic stress MPI is a technology primarily used and studied for its role in advanced cardiac evaluation of symptoms suspected of representing CHD and/or estimation of prognosis in patients with known coronary artery disease.) I IIa IIb III I IIa IIb III

What about coronary CTA? Currently used to identify or exclude stenosis in symptomatic patients Prognostic power in this role? Role in the asymptomatic individual?

R/o Stenoses in Symptomatic Patients 421 patients with stable chest pain and positive SPECT (“intermediate risk“): 64 slice CT 78 Pt: Coronary angiography (50 revasc., 1MI, 1†) 343 Pt: Medical 15 month FU: 6 Coronary Angiographies 1 Revascularization Am J Cardiol 2007

R/o Stenoses in Symptomatic Patients 421 patients with stable chest pain and positive SPECT (“intermediate risk“): 64 slice CT 78 Pt: Coronary angiography (50 revasc., 1MI, 1†) 343 Pt: Medical 15 month FU: 6 Coronary Angiographies 1 Revascularization Am J Cardiol 2007

R/o Stenoses in Symptomatic Patients 421 patients with stable chest pain and positive SPECT (“intermediate risk“): 64 slice CT 78 Pt: Coronary angiography (50 revasc., 1MI, 1†) 343 Pt: Medical 15 month FU: 6 Coronary Angiographies 1 Revascularization Am J Cardiol 2007

R/o Stenoses in Symptomatic Patients 2230 patients with suspected CAD 64 slice CT or DSCT Cardiac Death, MI, unstable angina, revascularization > 90 days after CT “Clean Coronaries“: 0% event rate/year No stenosis: 0.3% event rate/year Stenosis > 50%: 3.9% event rate/year Stenosis > 75%: 4.2% event rate/year Hadamitzky et al, Circ CV Imaging 2010

R/o Stenoses in Symptomatic Patients 486 acute chest pain patients in ER, low TIMI score 64 slice CT 84% discharged home after normal CT No events in 30 days (vs. 7) 1 year (481 pts): 1 unclear death, no MI Ann Emerg Med 2009 Acad Emerg Med 2009

R/o Stenoses in Symptomatic Patients “Close to zero” event rate after ruling out coronary stenosis by CT in symptomatic patients Stable Chest Pain Hadamitzki et al, iJACC 2009 Lesser et al, Cath Card Interv 2007 Danciu et al, Am J Cardiol 2007 Schussler et al, Am J Cardiol 2009 Ostrom et al, JACC 2008 Abidov et al, J Nucl Cardiol 2009 Chow et al, JACC 2010 Acute Chest Pain Rubinshtein et al, AJC 2007 Hollander et al, Ann Emerg Med 2009

Non-stenotic Plaque? 2076 Patients without known CAD 64-slice CT 2 years follow-up: Death, non-fatal MI (n = 47) CT normal: 0.1%/year Plaque: 0.5%/year Stenosis: 2.7%/year Chow et al, JACC 2010

Non-stenotic Plaque? ≤ 5 segments >5 Segments Segment Involvement Score: 0 = no plaque 1 = plaque present max. 16 for 16 segments ≤ 5 segments >5 Segments Min et al, JACC 2007

Non-stenotic Plaque? 2538 pts. , EBT-CTA. 12 years f/u („survival“). Ostrom et al, JACC 2008

Non-stenotic Plaque? Meta Analysis: 9952 symptomatic patients 20 months f/u – Death, MI, Revasc. - LR= 0.008 (strong) but + LR =1.7 (weak) J Am Coll Cardiol 2011

Non-stenotic Plaque? Meta Analysis: 9952 symptomatc patients 20 months f/u – Death, MI, Revasc. - LR= 0,008 (strong) + LR =1.7 (weak) J Am Coll Cardiol 2011

Non-stenotic Plaque? Low event rates overall. Very low event rates in patients without stenoses, but plaque in CT indicates somewhat elevated risk Plaque seemingly has to be rather extensive (3 vessels, 5 segments)

Non-stenotic Plaque? Some plaque features seem to indicate especially high risk: Low density, positive remodeling

Non-stenotic Plaque? 1039 symptomatic patients coronary segments > 2 mm Positive remodeling? Low attenuation (< 30 HU)? Motoyama, JACC 2009

Asymptomatic Individuals? 451 asymptomatc individuals. 229 (54%) had nonobstructive plaque 107 (24%) had obstructive disease 28 months follow up: 2 cases of unstable angina 8 cases of revascularization for stable angina 2 pts, unstable angina 8 pts, PCI for stable angina Am J Cardiol 2010

Asymptomatic Individuals? 451 asymptomatc individuals. 229 (54%) had nonobstructive plaque 107 (24%) had obstructive disease 28 months follow up: 2 cases of unstable angina 8 cases of revascularization for stable angina 2 pts, unstable angina 8 pts, PCI for stable angina Am J Cardiol 2010

Asymptomatic Individuals? 451 asymptomatc individuals. 229 (54%) had nonobstructive plaque 107 (24%) had obstructive disease 28 months follow up: 2 cases of unstable angina 8 cases of revascularization for stable angina 2 pts, unstable angina 8 pts, PCI for stable angina Am J Cardiol 2010

Asymptomatic Individuals? In truly asymptomatic individuals, overall event rates are very low. Contribution of coronary CT angiography as a “screening“is questionable.

Appropriateness Criteria

Appropriateness Criteria

Appropriateness Criteria

Summary Coronary calcium scanning predicts CHD events, independent of and in addition to clinical risk stratification Best suited for intermediate and low-to-intermediate risk population Absence of coronary calcium confers excellent prognosis In symptomatic individuals, absence of plaque associated with excellent outcome… …and absence of stenosis associated with good outcome… …but in asymptomatic individuals, there is no role for coronary CTA for risk stratification

Thank you